- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01613768
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Evaluate the response rate of eribulin per Response Evaluation Criteria In Solid Tumors (RECIST) in patients with locally advanced refractory or metastatic salivary gland cancer (SGC).
SECONDARY OBJECTIVES:
I. Determine the safety and toxicity of eribulin in patients with locally advanced refractory or metastatic SGC.
II. Evaluate the duration of response and time-to-progression.
OUTLINE:
Patients receive eribulin mesylate intravenously (IV) over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have histologically or cytologically documented salivary gland cancers; patients that do not have a salivary gland primary must have one of the following histologies - adenoid cystic carcinoma, mucoepidermoid carcinoma, acinic cell carcinoma
- Patients must have recurrent and/or metastatic disease that is progressive and not amenable to surgery or curative radiotherapy occurring within 6 months of study entry, as evidenced by: at least a 20% increase in radiographically or clinically measurable disease, appearance of any new lesions, or deterioration in clinical status
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Patients with measurable disease per RECIST 1.1 criteria
- At least one lesion of >= 1.5 cm in long-axis diameter for non lymph nodes or >= 1.5 cm in short-axis diameter for lymph nodes which is serially measurable according to RECIST 1.1 using either computerized tomography (CT) or magnetic resonance imaging (MRI)
- Lesions that have had radiotherapy must show evidence of progressive disease (PD) based on RECIST 1.1 to be deemed a target lesion
- Absolute neutrophil count >= 1,500/μL
- Platelets >= 100,000/μL
- Creatinine clearance >= 40 mL/min
- Bilirubin =< 1.5 upper limit of normal (ULN)
- Alkaline phosphatase =< 3 ULN; if total ALP is > 3 x ULN (in the absence of liver metastasis) or > 5 x ULN in subjects with liver metastasis AND the subject is known to have bone metastases, then liver ALP iso-enzyme should be used to assess liver function rather than total ALP
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN
- Women of child-bearing potential (WOCP) and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation
- Life expectancy of > 12 weeks
- Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrollment
Exclusion Criteria:
- Patients with symptomatic central nervous system (CNS) metastases must have stable disease after treatment with surgery or radiation therapy
- Second primary malignancy that is clinically detectable or clinically significant at the time of consideration for study enrollment
- Radiotherapy within 14 days of study treatment
- Major surgery within 21 days of study treatment; minor surgery within 2 weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered major or minor surgery
- Treatment with any chemotherapy or investigational agents within 4 weeks of the start of study treatment; subjects must have recovered from toxicities of prior therapy
- Patients with peripheral neuropathy >= grade 2
- Significant cardiovascular impairment: congestive heart failure > class II according to the New York Heart Association (NYHA), unstable angina or myocardial infarction within 6 months of enrollment, or serious cardiac arrhythmia (> grade 2)
- Concomitant severe or uncontrolled medical disease
- Significant psychiatric or neurologic disorder which would compromise participation in the study
- Pregnant or breast-feeding females
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (eribulin mesylate)
Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate
Time Frame: From date of first study therapy until date of first documented disease progression or date of death from any cause, unacceptable toxicity or withdrawal of patient consent, whichever occurred first, assessed up to 36 days post last dose of study therapy.
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by either CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR, summarized using frequencies and percentages.
|
From date of first study therapy until date of first documented disease progression or date of death from any cause, unacceptable toxicity or withdrawal of patient consent, whichever occurred first, assessed up to 36 days post last dose of study therapy.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Tumor Response (Complete (CR) and Partial (PR) Response Only)
Time Frame: From date of first study therapy until date of first documented disease progression or date of death from any cause, unacceptable toxicity or withdrawal of patient consent, whichever occurred first, assessed up to 36 days post last dose of study therapy.
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by either CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR, reported as median values.
|
From date of first study therapy until date of first documented disease progression or date of death from any cause, unacceptable toxicity or withdrawal of patient consent, whichever occurred first, assessed up to 36 days post last dose of study therapy.
|
Time to Progression
Time Frame: From date of first study therapy until date of first documented disease progression or date of death from any cause, whichever occurred first, assessed up to 36 days post last dose of study therapy.
|
Either 1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by either CT or MRI: Progressive Disease (PD), > 20% increase in the sum of the longest diameter (SLD) target lesions taking as reference the smallest SLD recorded since the treatment started (nadir) and minimum 5 mm increase over the nadir; or 2. Radiographic progression per treating physician CT or MRI scan review.
|
From date of first study therapy until date of first documented disease progression or date of death from any cause, whichever occurred first, assessed up to 36 days post last dose of study therapy.
|
Disease Control Rate (DCR)
Time Frame: From date of first study therapy until date of first documented disease progression or date of death from any cause, unacceptable toxicity or withdrawal of patient consent, whichever occurred first, assessed up to 36 days post last dose of study therapy.
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by either CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage (compared to baseline) to qualify for partial or complete response (CR or PR) nor sufficient increase (taking as reference the smallest sum of diameters at baseline or while on study, whichever is smallest) to qualify for progressive disease (PD); Disease Control Rate (DCR) = CR + PR +SD.
|
From date of first study therapy until date of first documented disease progression or date of death from any cause, unacceptable toxicity or withdrawal of patient consent, whichever occurred first, assessed up to 36 days post last dose of study therapy.
|
Toxicity Rates
Time Frame: Adverse events collected from the time patient received the first dose of study therapy through 36 days following the last dose of study therapy or the start of a new cancer therapy, whichever occurred first, assessed up to 36 days post therapy.
|
Overall percentage of patients experiencing Grade 3 or higher toxicity, graded by National Cancer Institute (NCI) Common Toxicity Criteria Version 4.0
|
Adverse events collected from the time patient received the first dose of study therapy through 36 days following the last dose of study therapy or the start of a new cancer therapy, whichever occurred first, assessed up to 36 days post therapy.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Renato Martins, MD, MPH, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7674 (Other Identifier: CTEP)
- NCI-2012-00892 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Salivary Gland Cancer
-
NRG OncologyNational Cancer Institute (NCI)RecruitingRecurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland CarcinomaUnited States
-
Mayo ClinicRecruitingRecurrent Salivary Gland Carcinoma | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland CarcinomaUnited States
-
University Health Network, TorontoActive, not recruitingSalivary Gland Cancer | Metastatic | Recurrent | AdvancedCanada
-
Samsung Medical CenterUnknownRecurrent or Metastatic Salivary Gland Cancer of the Head and NeckKorea, Republic of
-
National Cancer Institute (NCI)Southwest Oncology GroupCompletedRecurrent Salivary Gland Cancer | Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Stage III Adenoid Cystic Carcinoma of the Oral Cavity | Stage III Salivary Gland Cancer | Stage IV Adenoid Cystic Carcinoma of the Oral Cavity | Stage IV Salivary Gland Cancer | Salivary Gland Adenoid Cystic...United States
-
National Cancer Institute (NCI)TerminatedRecurrent Salivary Gland Cancer | Stage IVA Salivary Gland Cancer | Stage IVB Salivary Gland Cancer | Stage IVC Salivary Gland Cancer | High-grade Salivary Gland Mucoepidermoid Carcinoma | Salivary Gland Acinic Cell Tumor | Salivary Gland Adenocarcinoma | Salivary Gland Poorly Differentiated CarcinomaUnited States
-
Glenn J. HannaActuate Therapeutics Inc.Active, not recruitingAdenoid Cystic Carcinoma | Metastatic Cancer | Salivary Gland Cancer | Recurrent Salivary Gland CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Salivary Gland Cancer | Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | High-grade Salivary Gland Carcinoma | High-grade Salivary Gland Mucoepidermoid Carcinoma | Low-grade Salivary Gland Carcinoma | Low-grade Salivary Gland Mucoepidermoid Carcinoma | Salivary Gland Acinic Cell... and other conditionsCanada
-
National Cancer Institute (NCI)CompletedRecurrent Salivary Gland Carcinoma | Salivary Gland Adenoid Cystic Carcinoma | Stage IV Major Salivary Gland Cancer AJCC v7 | Malignant Salivary Gland NeoplasmUnited States, Canada
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)Active, not recruitingMajor Salivary Gland Carcinoma | Recurrent Salivary Gland Carcinoma | Stage IVA Major Salivary Gland Carcinoma | Stage IVB Major Salivary Gland Carcinoma | Stage IVC Major Salivary Gland Carcinoma | Minor Salivary Gland Carcinoma | Stage IV Major Salivary Gland CarcinomaUnited States
Clinical Trials on eribulin mesylate
-
Zhejiang Cancer HospitalNot yet recruiting
-
Eisai LimitedCompletedAdvanced Solid TumorFrance
-
Eisai Korea Inc.CompletedBreast Cancer | Breast NeoplasmsKorea, Republic of
-
Eisai Inc.Approved for marketingMetastatic Breast CancerCanada, Belgium, France
-
Eisai Inc.Completed
-
Eisai Co., Ltd.Completed
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruitingTriple Negative Breast CancerChina
-
National Cancer Institute (NCI)CompletedHead and Neck CancerUnited States
-
Hunan Cancer HospitalCompletedMetastatic Breast CancerChina
-
Oncologia Medica dell'Ospedale FatebenefratelliMario Negri Institute for Pharmacological ResearchCompletedMetastatic Breast Cancer | Toxicity | Neurotoxicity | Adverse Drug Event | Drug ToxicityItaly